Primary Care Diabetes最新文献

英文中文

Trends in metabolic risk factors control among adults with type 2 diabetes: A comparative study of 2018 and 2021 成人2型糖尿病患者代谢危险因素控制趋势：2018年和2021年的比较研究

IF 2.3 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Primary Care Diabetes

Pub Date : 2025-07-03 DOI: 10.1016/j.pcd.2025.06.008

Fereshteh Baygi, Peter Haastrup, Helene Støttrup Andersen, Sonja Wehberg, Jens Søndergaard

Aims

This study aims to analyze recent trends in managing major metabolic risk factors among type 2 diabetes patients (T2D) over time.

Methods

We used data from the Danish Adult Diabetes Registry (DVDD) on health indicators in 2018 and 2021. Information about medication was found using Danish National Prescription Registry (DNPR). Cut points for abnormal values of the included health indicators were identified from the revised National Cholesterol Education Program Adult Treatment Panel III criteria. Correspondingly, reached target levels were defined. A logistic regression model based on generalized estimating equations was fitted to evaluate the difference between 2018 and 2021.

Results

We included 24,343 and 18,027 observations in 2018 and 2021, respectively. Longitudinal analyses showed statistically significant improvement in Low density lipoprotein, Blood pressure, triglycerides, and Glycated hemoglobin control overtime. The use of glucose-lowering and lipid-lowering medications, and antihypertensive medication increased. Obesity declined significantly overtime. Subgroup analyses highlighted improvement in metabolic control across age groups, with TG control declining in T2D patients over 60 years.

Conclusions

We found statistically significant improvement in metabolic risk factor control and medication use over time. Despite progress in managing LDL, BP, and HbA1c, challenges remain in Blood pressure and triglycerides control.

目的：本研究旨在分析2型糖尿病患者（T2D）主要代谢危险因素管理的最新趋势。方法：我们使用了丹麦成人糖尿病登记处（DVDD） 2018年和2021年健康指标的数据。使用丹麦国家处方登记处（DNPR）查找有关药物的信息。从修订后的国家胆固醇教育计划成人治疗小组III标准中确定了所包括健康指标异常值的切点。相应地，确定了达到的目标水平。拟合基于广义估计方程的logistic回归模型，评估2018年与2021年的差异。结果：我们在2018年和2021年分别纳入了24,343和18,027项观察结果。纵向分析显示，随着时间的推移，低密度脂蛋白、血压、甘油三酯和糖化血红蛋白的控制有统计学意义的改善。降糖、降脂药物和抗高血压药物的使用增加。随着时间的推移，肥胖率显著下降。亚组分析强调了各年龄组代谢控制的改善，60岁以上T2D患者的TG控制下降。结论：我们发现随着时间的推移，代谢危险因素控制和药物使用有统计学意义的改善。尽管在控制LDL、BP和HbA1c方面取得了进展，但在血压和甘油三酯控制方面仍然存在挑战。

{"title":"Trends in metabolic risk factors control among adults with type 2 diabetes: A comparative study of 2018 and 2021","authors":"Fereshteh Baygi, Peter Haastrup, Helene Støttrup Andersen, Sonja Wehberg, Jens Søndergaard","doi":"10.1016/j.pcd.2025.06.008","DOIUrl":"10.1016/j.pcd.2025.06.008","url":null,"abstract":"<div><h3>Aims</h3><div>This study aims to analyze recent trends in managing major metabolic risk factors among type 2 diabetes patients (T2D) over time.</div></div><div><h3>Methods</h3><div>We used data from the Danish Adult Diabetes Registry (DVDD) on health indicators in 2018 and 2021. Information about medication was found using Danish National Prescription Registry (DNPR). Cut points for abnormal values of the included health indicators were identified from the revised National Cholesterol Education Program Adult Treatment Panel III criteria. Correspondingly, reached target levels were defined. A logistic regression model based on generalized estimating equations was fitted to evaluate the difference between 2018 and 2021.</div></div><div><h3>Results</h3><div>We included 24,343 and 18,027 observations in 2018 and 2021, respectively. Longitudinal analyses showed statistically significant improvement in Low density lipoprotein, Blood pressure, triglycerides, and Glycated hemoglobin control overtime. The use of glucose-lowering and lipid-lowering medications, and antihypertensive medication increased. Obesity declined significantly overtime. Subgroup analyses highlighted improvement in metabolic control across age groups, with TG control declining in T2D patients over 60 years.</div></div><div><h3>Conclusions</h3><div>We found statistically significant improvement in metabolic risk factor control and medication use over time. Despite progress in managing LDL, BP, and HbA1c, challenges remain in Blood pressure and triglycerides control.</div></div>","PeriodicalId":48997,"journal":{"name":"Primary Care Diabetes","volume":"19 5","pages":"Pages 486-496"},"PeriodicalIF":2.3,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between continuous glucose monitoring derived metrics and clinical parameters in Indian people living with type 2 diabetes 印度2型糖尿病患者连续血糖监测指标与临床参数的关系

IF 2.3 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Primary Care Diabetes

Pub Date : 2025-06-27 DOI: 10.1016/j.pcd.2025.06.004

Purvi Chawla , Alpana Sowani , Rakesh Parikh , Amit Gupta , Jothydev Kesavadev , Rutul Gokalani , Banshi Saboo , Manoj Chawla

Background

To evaluate the correlation between continuous glucose monitoring (CGM)-derived metrics such as time in range (TIR) and time below range (TBR) and clinical parameters in Indian patients with type 2 diabetes mellitus (T2DM), providing insights into the effectiveness of CGM in this population.

Methods

This is a single-center, retrospective-observational study of T2DM patients aged 18 or older years using the Freestyle Libre/Libre Pro CGM system. Demographic and clinical data of these patients were extracted from medical records, and glycemic metrics from CGM profiles.

Results

The study included 248 T2DM patients, of whom 72.98 % were male, with a mean age of 60.48 years and a mean HbA1c value of 8.319 %. Linear regression analysis revealed that TIR was significantly negatively associated with HbA1c values (coefficient=-6.746) and duration of diabetes (coefficient=-0.425). The body mass index (BMI) showed a positive association with TIR (coefficient=0.649; P = 0.032). For TBR, only HbA1c values showed a significant negative association (coefficient=-1.051; P = 0.009), whereas age, duration of diabetes, and BMI were not significant predictors.

Conclusion

The study highlights the significant relationships between CGM-derived metrics (TIR and TBR), and clinical parameters in Indian patients with T2DM, and their effectiveness in identifying patients at risk of inadequate glycemic control.

背景：评估印度2型糖尿病（T2DM）患者连续血糖监测（CGM）衍生指标（如范围内时间（TIR）和范围下时间（TBR））与临床参数之间的相关性，为CGM在该人群中的有效性提供见解。方法：这是一项使用Freestyle Libre/Libre Pro CGM系统的18岁及以上T2DM患者的单中心、回顾性观察研究。这些患者的人口学和临床数据从医疗记录中提取，血糖指标从CGM档案中提取。结果：研究纳入T2DM患者248例，其中男性72.98 %，平均年龄60.48岁，平均HbA1c值8.319 %。线性回归分析显示，TIR与HbA1c值（系数=-6.746）和糖尿病病程（系数=-0.425）呈显著负相关。体质指数（BMI）与TIR呈正相关(系数=0.649； = 0.032页)。对于TBR，只有HbA1c值呈显著负相关(系数=-1.051；P = 0.009)，而年龄、糖尿病病程和BMI不是显著的预测因子。结论：该研究强调了cgm衍生指标（TIR和TBR）与印度T2DM患者临床参数之间的显著关系，以及它们在识别血糖控制不足风险患者方面的有效性。

{"title":"Association between continuous glucose monitoring derived metrics and clinical parameters in Indian people living with type 2 diabetes","authors":"Purvi Chawla , Alpana Sowani , Rakesh Parikh , Amit Gupta , Jothydev Kesavadev , Rutul Gokalani , Banshi Saboo , Manoj Chawla","doi":"10.1016/j.pcd.2025.06.004","DOIUrl":"10.1016/j.pcd.2025.06.004","url":null,"abstract":"<div><h3>Background</h3><div>To evaluate the correlation between continuous glucose monitoring (CGM)-derived metrics such as time in range (TIR) and time below range (TBR) and clinical parameters in Indian patients with type 2 diabetes mellitus (T2DM), providing insights into the effectiveness of CGM in this population.</div></div><div><h3>Methods</h3><div>This is a single-center, retrospective-observational study of T2DM patients aged 18 or older years using the Freestyle Libre/Libre Pro CGM system. Demographic and clinical data of these patients were extracted from medical records, and glycemic metrics from CGM profiles.</div></div><div><h3>Results</h3><div>The study included 248 T2DM patients, of whom 72.98 % were male, with a mean age of 60.48 years and a mean HbA1c value of 8.319 %. Linear regression analysis revealed that TIR was significantly negatively associated with HbA1c values (coefficient=-6.746) and duration of diabetes (coefficient=-0.425). The body mass index (BMI) showed a positive association with TIR (coefficient=0.649; <em>P</em> = 0.032). For TBR, only HbA1c values showed a significant negative association (coefficient=-1.051; <em>P</em> = 0.009), whereas age, duration of diabetes, and BMI were not significant predictors.</div></div><div><h3>Conclusion</h3><div>The study highlights the significant relationships between CGM-derived metrics (TIR and TBR), and clinical parameters in Indian patients with T2DM, and their effectiveness in identifying patients at risk of inadequate glycemic control.</div></div>","PeriodicalId":48997,"journal":{"name":"Primary Care Diabetes","volume":"19 5","pages":"Pages 453-461"},"PeriodicalIF":2.3,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144512962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial Board and Aims & Scopes 编辑委员会和目标与范围

IF 2.6 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Primary Care Diabetes

Pub Date : 2025-06-25 DOI: 10.1016/S1751-9918(25)00120-2

引用次数: 0

Back Matter 2 : Society News 时事2：社会新闻

IF 2.6 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Primary Care Diabetes

Pub Date : 2025-06-25 DOI: 10.1016/S1751-9918(25)00126-3

引用次数: 0

Back Matter 1 : Colophon PCD 背面材料1:Colophon PCD

IF 2.6 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Primary Care Diabetes

Pub Date : 2025-06-25 DOI: 10.1016/S1751-9918(25)00125-1

引用次数: 0

Pattern of semaglutide prescription in a real-world Canadian patient cohort 西马鲁肽在加拿大真实患者队列中的处方模式。

IF 2.3 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Primary Care Diabetes

Pub Date : 2025-06-24 DOI: 10.1016/j.pcd.2025.06.006

Armin Farahvash , Michelle CM Lee , Rahul Jain , Liisa Jaakkimainen

Aims

Despite the growing interest in the broad applications of semaglutide, real-world data on its use in weight-loss is limited. This study aims to explore the pattern of semaglutide prescriptions in a Canadian family medicine practice.

Methods

This retrospective study included patients ≥ 18 years who were enrolled in Sunnybrook Academic Family practice in Toronto, Canada and prescribed semaglutide between January 2018 and April 2024. Baseline demographics, weight measurements up to 16 months, and prescription details were collected. Descriptive statistics was used to illustrate the patterns of semaglutide prescription.

Results

Of 9930 enrolled patients, 368 (3.71 %) were prescribed semaglutide and 335 used it. Mean age was 57.7 ± 14.1 years and 63.3 % were female. Mean BMI was 36.6 ± 7.84 kg/m². Semaglutide was discontinued due to side effects in 11 (3.3 %) within one month and 27 (8.1 %) at any time. There was an increasing trend in semaglutide prescriptions from 2018 to 2023. There were increasing semaglutide prescriptions for weight-loss, and prescriptions by family physicians compared to specialists. Follow up measurements showed a mean weight-loss of 7.5 % in 212 patients.

Conclusions

In an Ontario academic family practice, semaglutide is being more frequently prescribed in the primary care setting, particularly for weight loss.

目的：尽管人们对西马鲁肽的广泛应用越来越感兴趣，但其在减肥中的实际应用数据有限。本研究旨在探讨西马鲁肽处方模式在加拿大家庭医学实践。方法：本回顾性研究纳入≥ 18岁的患者，这些患者于2018年1月至2024年4月在加拿大多伦多Sunnybrook学术家庭诊所登记，并服用了西马鲁肽。收集了基线人口统计数据、16个月前的体重测量数据和处方细节。描述性统计用于说明西马鲁肽处方的模式。结果：在9930例入组患者中，368例（3.71 %）处方了西马鲁肽，335例使用了西马鲁肽。平均年龄57.7 ± 14.1岁，女性63.3% %。平均BMI为36.6 ± 7.84 kg/m2。11例（3.3 %）患者在1个月内因副作用停药，27例（8.1 %）患者在任何时间停药。2018 - 2023年，西马鲁肽处方呈增加趋势。与专科医生相比，家庭医生开具的用于减肥的西马鲁肽处方越来越多。随访测量显示212例患者的平均体重减轻了7.5% %。结论：在安大略省的学术家庭实践中，西马鲁肽在初级保健环境中被更频繁地开处方，特别是减肥。

{"title":"Pattern of semaglutide prescription in a real-world Canadian patient cohort","authors":"Armin Farahvash , Michelle CM Lee , Rahul Jain , Liisa Jaakkimainen","doi":"10.1016/j.pcd.2025.06.006","DOIUrl":"10.1016/j.pcd.2025.06.006","url":null,"abstract":"<div><h3>Aims</h3><div>Despite the growing interest in the broad applications of semaglutide, real-world data on its use in weight-loss is limited. This study aims to explore the pattern of semaglutide prescriptions in a Canadian family medicine practice.</div></div><div><h3>Methods</h3><div>This retrospective study included patients ≥ 18 years who were enrolled in Sunnybrook Academic Family practice in Toronto, Canada and prescribed semaglutide between January 2018 and April 2024. Baseline demographics, weight measurements up to 16 months, and prescription details were collected. Descriptive statistics was used to illustrate the patterns of semaglutide prescription.</div></div><div><h3>Results</h3><div>Of 9930 enrolled patients, 368 (3.71 %) were prescribed semaglutide and 335 used it. Mean age was 57.7 ± 14.1 years and 63.3 % were female. Mean BMI was 36.6 ± 7.84 kg/m<sup>2</sup>. Semaglutide was discontinued due to side effects in 11 (3.3 %) within one month and 27 (8.1 %) at any time. There was an increasing trend in semaglutide prescriptions from 2018 to 2023. There were increasing semaglutide prescriptions for weight-loss, and prescriptions by family physicians compared to specialists. Follow up measurements showed a mean weight-loss of 7.5 % in 212 patients.</div></div><div><h3>Conclusions</h3><div>In an Ontario academic family practice, semaglutide is being more frequently prescribed in the primary care setting, particularly for weight loss.</div></div>","PeriodicalId":48997,"journal":{"name":"Primary Care Diabetes","volume":"19 5","pages":"Pages 512-516"},"PeriodicalIF":2.3,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144499983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Non-insulin-based markers of insulin resistance at diabetes diagnosis: A pooled analysis of 14 national health surveys 糖尿病诊断中胰岛素抵抗的非胰岛素基础标志物：对14个国家健康调查的汇总分析

IF 2.3 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Primary Care Diabetes

Pub Date : 2025-06-16 DOI: 10.1016/j.pcd.2025.06.005

Rodrigo M. Carrillo-Larco , Wilmer Cristobal Guzman-Vilca , Xiaolin Xu , Antonio Bernabe-Ortiz

Background

The extent to which people with newly diagnosed diabetes exhibit similar insulin resistance profiles across countries is unknown. Understanding the heterogeneity in glycemic and cardiometabolic profiles at the time of diabetes diagnosis could provide insights for precision medicine.

Methods

We analyzed 14 nationally representative surveys (STEPS). We used anthropometric measures, fasting glucose, triglycerides and HDL cholesterol to calculate eight non-insulin-based markers of insulin resistance: triglyceride and glucose ratio (TyG), TyG with BMI (TyGBMI), TyG with waist circumference (TyGwaist), TyG with waist-to-height ratio (TyGWHtR), triglyceride-to-HDL ratio (TGHDL_r), metabolic score for insulin resistance (METS-IR), lipid accumulation product (LAP), and visceral adiposity index (VAI). We only included subjects with newly diagnosed diabetes. Age- and sex-adjusted multilevel linear regression models were used to estimate country-specific margins of the z-scores for each insulin resistance surrogate (_z suffix refers to predicted z-score margins).

Results

A total of 2531 individuals were analyzed (mean age 47.4 years; 56.6 % were women). The widest disparities across countries in predicted z-scores were observed for TyG-based markers. For instance, the predicted margins for TyGBMI_z ranged from −0.985 (Ethiopia) to 0.682 (Kuwait). In contrast, narrower disparities were noted for other markers, with the smallest gap observed for VAI_z ranging from −0.688 (Bhutan) to 0.491 (Guyana).

Conclusions

The study highlights heterogeneity in metabolic profiles at diabetes diagnosis across countries. These findings emphasize the importance of incorporating population-specific factors into strategies for understanding and addressing the global diabetes burden, particularly in recognizing the diverse cardiometabolic profiles at the time of diagnosis.

背景：各国新诊断的糖尿病患者在多大程度上表现出相似的胰岛素抵抗特征尚不清楚。了解糖尿病诊断时血糖和心脏代谢谱的异质性可以为精准医学提供见解。方法：我们分析了14项全国代表性调查（STEPS）。我们使用人体测量、空腹血糖、甘油三酯和高密度脂蛋白胆固醇来计算胰岛素抵抗的八种非胰岛素基础标志物：甘油三酯与葡萄糖比（TyG）、TyG与BMI （TyGBMI）、TyG与腰围（tyg腰部）、TyG与腰高比（TyGWHtR）、甘油三酯与高密度脂蛋白比（TGHDL_r）、胰岛素抵抗代谢评分（METS-IR）、脂质积累产物（LAP）和内脏脂肪指数（VAI）。我们只纳入了新诊断的糖尿病患者。使用年龄和性别调整的多水平线性回归模型来估计每个胰岛素抵抗替代指标的z分数的国家特定边际（_z后缀指预测的z分数边际）。结果：共分析2531例个体(平均年龄47.4岁；56.6% %为女性)。在基于tyg的标记中，预测z分数的差异在各国之间最大。例如，TyGBMI_z的预测边际范围从-0.985（埃塞俄比亚）到0.682（科威特）。相比之下，其他指标的差距较小，VAI_z的最小差距从-0.688（不丹）到0.491（圭亚那）不等。结论：该研究强调了各国糖尿病诊断中代谢谱的异质性。这些发现强调了将人群特异性因素纳入了解和解决全球糖尿病负担的策略的重要性，特别是在诊断时认识到不同的心脏代谢谱。

{"title":"Non-insulin-based markers of insulin resistance at diabetes diagnosis: A pooled analysis of 14 national health surveys","authors":"Rodrigo M. Carrillo-Larco , Wilmer Cristobal Guzman-Vilca , Xiaolin Xu , Antonio Bernabe-Ortiz","doi":"10.1016/j.pcd.2025.06.005","DOIUrl":"10.1016/j.pcd.2025.06.005","url":null,"abstract":"<div><h3>Background</h3><div>The extent to which people with newly diagnosed diabetes exhibit similar insulin resistance profiles across countries is unknown. Understanding the heterogeneity in glycemic and cardiometabolic profiles at the time of diabetes diagnosis could provide insights for precision medicine.</div></div><div><h3>Methods</h3><div><span><span>We analyzed 14 nationally representative surveys (STEPS). We used anthropometric measures, fasting glucose, </span>triglycerides<span> and HDL cholesterol to calculate eight non-insulin-based markers of insulin resistance: triglyceride and glucose ratio (TyG), TyG with </span></span>BMI<span><span><span> (TyGBMI), TyG with waist circumference (TyGwaist), TyG with waist-to-height ratio (TyGWHtR), triglyceride-to-HDL ratio (TGHDL_r), metabolic score for insulin resistance (METS-IR), lipid accumulation product (LAP), and visceral </span>adiposity index (VAI). We only included subjects with newly diagnosed diabetes. Age- and sex-adjusted multilevel </span>linear regression models were used to estimate country-specific margins of the z-scores for each insulin resistance surrogate (_z suffix refers to predicted z-score margins).</span></div></div><div><h3>Results</h3><div>A total of 2531 individuals were analyzed (mean age 47.4 years; 56.6 % were women). The widest disparities across countries in predicted z-scores were observed for TyG-based markers. For instance, the predicted margins for TyGBMI_z ranged from −0.985 (Ethiopia) to 0.682 (Kuwait). In contrast, narrower disparities were noted for other markers, with the smallest gap observed for VAI_z ranging from −0.688 (Bhutan) to 0.491 (Guyana).</div></div><div><h3>Conclusions</h3><div>The study highlights heterogeneity in metabolic profiles at diabetes diagnosis across countries. These findings emphasize the importance of incorporating population-specific factors into strategies for understanding and addressing the global diabetes burden, particularly in recognizing the diverse cardiometabolic profiles at the time of diagnosis.</div></div>","PeriodicalId":48997,"journal":{"name":"Primary Care Diabetes","volume":"19 5","pages":"Pages 497-503"},"PeriodicalIF":2.3,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144319078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tobacco, electronic cigarette, alcohol and cannabis use among individuals diagnosed with diabetes. A national survey in France 糖尿病患者使用烟草、电子烟、酒精和大麻的情况。法国的一项全国性调查。

IF 2.3 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Primary Care Diabetes

Pub Date : 2025-06-13 DOI: 10.1016/j.pcd.2025.06.002

Ivan Berlin , Romain Guignard , Sandrine Fosse-Edorh , Guillemette Quatremère , Emmanuel Lahaie , Viêt Nguyen-Thanh

Aims

To evaluate the prevalence of tobacco smoking, electronic cigarette, alcohol and cannabis use among individuals diagnosed with diabetes mellitus (wD) compared to those who were not (woD).

Methods

Data of the French Health Barometer 2021 were analyzed.

Results

A total of 24,496 individuals completed the survey; of whom 1772 (8.0 %) reported living with diabetes. There were significantly fewer smokers among individuals wD (22.1 % vs. 30.6 %), but more former and fewer never smokers. Smoking more than 15 cigarettes/day was more common among those wD and they were more tobacco dependent than those woD. 28.7 % of persons wD and 39.5 % woD reported having already tried electronic cigarettes. Current or daily electronic cigarette use was similar. Among those who had tried e-cigarettes, 5.7 % of respondents wD were never smokers (vs. 10.1 % of those woD). Alcohol consumption and cannabis use were significantly less common among respondents wD than those woD, but the prevalence of daily alcohol consumption was similar.

Conclusions

Although smoking prevalence is lower among persons wD compared to those without, smokers wD smoke more and are more tobacco dependent. Tobacco smoking should be assessed and all smokers wD should be enrolled in a smoking cessation program. More data are needed regarding other substance use and its association with diabetes characteristics and self-management.

目的：评估被诊断为糖尿病（wD）的个体与未被诊断为糖尿病（wD）的个体相比，吸烟、电子烟、酒精和大麻使用的流行程度。方法：对法国健康晴雨表2021的数据进行分析。结果：共有24496人完成调查；其中1772人（8.0 %）报告患有糖尿病。在wD个体中，吸烟者明显减少（22.1% % vs. 30.6% %），但吸烟者较多，从不吸烟者较少。d组每天吸烟超过15支更为普遍，他们比d组更依赖烟草。28.7% %的wD和39.5% %的wD报告已经尝试过电子烟。目前或每天使用电子烟的情况相似。在那些尝试过电子烟的人中，5.7% %的wD受访者从未吸烟（10.1% %的wD受访者从未吸烟）。在答复者wD中，酒精消费和大麻使用明显低于wD，但每日酒精消费的流行程度相似。结论：尽管糖尿病患者的吸烟率低于非糖尿病患者，但糖尿病吸烟者吸烟更多，更依赖烟草。应该对吸烟进行评估，所有吸烟者都应该参加戒烟计划。需要更多关于其他物质使用及其与糖尿病特征和自我管理的关系的数据。

{"title":"Tobacco, electronic cigarette, alcohol and cannabis use among individuals diagnosed with diabetes. A national survey in France","authors":"Ivan Berlin , Romain Guignard , Sandrine Fosse-Edorh , Guillemette Quatremère , Emmanuel Lahaie , Viêt Nguyen-Thanh","doi":"10.1016/j.pcd.2025.06.002","DOIUrl":"10.1016/j.pcd.2025.06.002","url":null,"abstract":"<div><h3>Aims</h3><div>To evaluate the prevalence of tobacco smoking, electronic cigarette, alcohol and cannabis use among individuals diagnosed with diabetes mellitus (wD) compared to those who were not (woD).</div></div><div><h3>Methods</h3><div>Data of the French Health Barometer 2021 were analyzed.</div></div><div><h3>Results</h3><div>A total of 24,496 individuals completed the survey; of whom 1772 (8.0 %) reported living with diabetes. There were significantly fewer smokers among individuals wD (22.1 % vs. 30.6 %), but more former and fewer never smokers. Smoking more than 15 cigarettes/day was more common among those wD and they were more tobacco dependent than those woD. 28.7 % of persons wD and 39.5 % woD reported having already tried electronic cigarettes. Current or daily electronic cigarette use was similar. Among those who had tried e-cigarettes, 5.7 % of respondents wD were never smokers (vs. 10.1 % of those woD). Alcohol consumption and cannabis use were significantly less common among respondents wD than those woD, but the prevalence of daily alcohol consumption was similar.</div></div><div><h3>Conclusions</h3><div>Although smoking prevalence is lower among persons wD compared to those without, smokers wD smoke more and are more tobacco dependent. Tobacco smoking should be assessed and all smokers wD should be enrolled in a smoking cessation program. More data are needed regarding other substance use and its association with diabetes characteristics and self-management.</div></div>","PeriodicalId":48997,"journal":{"name":"Primary Care Diabetes","volume":"19 5","pages":"Pages 478-485"},"PeriodicalIF":2.3,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144295539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Are children with familial type 1 diabetes from Kuwait different? Report on prevalence, clinical, biochemical, and immunological characteristics 科威特的家族性1型糖尿病患儿有何不同？报告患病率、临床、生化和免疫学特征。

IF 2.3 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Primary Care Diabetes

Pub Date : 2025-06-11 DOI: 10.1016/j.pcd.2025.06.001

Dalia Al-Abdulrazzaq , Mohammed T. Hudda , Doaa Khalifa Hussein , Hessa Alkandari

Introduction

This study aimed to determine prevalence of Familial FT1D children in type 1 diabetes in Kuwait and compare their characteristics at time of diagnosis including clinical phenotype, and biochemical/immunological profile in comparison to children with non-familial type 1 diabetes (NFT1D).

Methods

This is a population-based observational study of children registered in the Kuwait Childhood-Onset Diabetes electronic Registry (CODeR) between 2011 and 2022 at the time of T1D diagnosis. FT1D was defined as those reporting a first-degree relative with T1D.

Results

Out of 3494 diagnosed with T1D, 391 (11.2 %) had FT1D. The most common first degree relative affected were siblings (5.2 %). Children with FT1D had 49.6 % lower odds of presenting with DKA (p-value<0.001) and 33.4 % lower odds of PICU admission (p = 0.044). Levels of HbA1c were higher and C-peptides lower amongst children with FT1D (both p < 0.001). Children born to a mother with T1D had lower HbA1C (p < 0.001). Children with siblings with T1D lower odds of IAA (p = 0.003).

Conclusion

Children with FT1D in Kuwait had less likelihood of decompensation with a different pancreatic autoimmune profile according to the first degree relative in comparison to the literature. Future studies are required to study the course and outcomes of the disease in children with FT1D.

本研究旨在确定科威特家族性1型糖尿病患儿的患病率，并与非家族性1型糖尿病患儿（NFT1D）比较其诊断时的特征，包括临床表型和生化/免疫学特征。方法：这是一项基于人群的观察性研究，研究对象是2011年至2022年间在科威特儿童期糖尿病电子登记处（CODeR）登记的T1D诊断儿童。FT1D定义为报告有一级亲属患有T1D的患者。结果：在3494例诊断为T1D的患者中，391例（11.2 %）患有FT1D。最常见的一级亲属是兄弟姐妹（5.2 %）。FT1D患儿出现DKA的几率降低了49.6 % （p值）结论：与文献相比，科威特FT1D患儿具有不同的一级亲属胰腺自身免疫特征，代偿失代偿的可能性较小。未来的研究需要对FT1D患儿的病程和预后进行研究。

{"title":"Are children with familial type 1 diabetes from Kuwait different? Report on prevalence, clinical, biochemical, and immunological characteristics","authors":"Dalia Al-Abdulrazzaq , Mohammed T. Hudda , Doaa Khalifa Hussein , Hessa Alkandari","doi":"10.1016/j.pcd.2025.06.001","DOIUrl":"10.1016/j.pcd.2025.06.001","url":null,"abstract":"<div><h3>Introduction</h3><div>This study aimed to determine prevalence of Familial FT1D children in type 1 diabetes in Kuwait and compare their characteristics at time of diagnosis including clinical phenotype, and biochemical/immunological profile in comparison to children with non-familial type 1 diabetes (NFT1D).</div></div><div><h3>Methods</h3><div>This is a population-based observational study of children registered in the Kuwait Childhood-Onset Diabetes electronic Registry (CODeR) between 2011 and 2022 at the time of T1D diagnosis. FT1D was defined as those reporting a first-degree relative with T1D.</div></div><div><h3>Results</h3><div>Out of 3494 diagnosed with T1D, 391 (11.2 %) had FT1D. The most common first degree relative affected were siblings (5.2 %). Children with FT1D had 49.6 % lower odds of presenting with DKA (p-value<0.001) and 33.4 % lower odds of PICU admission (p = 0.044). Levels of HbA1c were higher and C-peptides lower amongst children with FT1D (both p < 0.001). Children born to a mother with T1D had lower HbA1C (p < 0.001). Children with siblings with T1D lower odds of IAA (p = 0.003).</div></div><div><h3>Conclusion</h3><div>Children with FT1D in Kuwait had less likelihood of decompensation with a different pancreatic autoimmune profile according to the first degree relative in comparison to the literature. Future studies are required to study the course and outcomes of the disease in children with FT1D.</div></div>","PeriodicalId":48997,"journal":{"name":"Primary Care Diabetes","volume":"19 5","pages":"Pages 533-539"},"PeriodicalIF":2.3,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144287687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of a primary care-based mobile health intervention to ‘sit less and move more’ on HbA1c, blood pressure, and other clinical outcomes in office employees with type 2 diabetes: A randomized controlled trial 基于初级保健的移动健康干预“少坐多动”对2型糖尿病办公室员工HbA1c、血压和其他临床结果的影响：一项随机对照试验

IF 2.3 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Primary Care Diabetes

Pub Date : 2025-06-09 DOI: 10.1016/j.pcd.2025.05.010

Francesc Alòs , Ma Àngels Colomer , Judit Bort-Roig , Carlos Martin-Cantera , Alicia Minaya , Ignasi Saigí , Miquel Sitjar-Suñer , Anna Puig-Ribera

Background

Type 2 diabetes (T2D) is a prevalent and costly disease, with sedentary behaviour and physical inactivity as modifiable contributors. Mobile health (mHealth) applications provide complementary strategies for T2D management, but their impact on clinical outcomes remains unclear.

Objective

This study evaluated the efficacy of an mHealth programme promoting “sit less and move more” at work, prescribed in clinical practice, on clinical and cardiovascular risk factors in office employees with T2D.

Methods

A randomized controlled trial compared usual care (n = 25) with a 13-week mHealth intervention (n = 29) using the Walk@Work-App and web-based tools. Outcomes included HbA1c, glycemia, lipid profile, domain-specific sedentary behaviour (Workforce Sitting Questionnaire), objective physical activity and sedentary behaviour (ActivPal), blood pressure, and BMI at baseline, 6, and 12 months.

Results

Compared to the control group and at 12 months, the intervention group showed a significant reduction in HbA1c (p < 0.05), systolic and diastolic blood pressure (p < 0.05). Sitting time decreased during leisure activities while watching TV (p = 0.0052) and using electronic devices (p = 0.0397). The number of sedentary breaks and time spent in sedentary bouts <20 min/day increased (p < 0.05).

Conclusions

An mHealth programme effectively reduced sedentary behaviour, improved HbA1c and blood pressure, serving as a cost-effective lifestyle intervention for adults with T2D.

Trial registration

ClinicalTrials.gov NCT04092738.https://clinicaltrials.gov/ct2/show/NCT04092738

背景：2型糖尿病（T2D）是一种普遍且昂贵的疾病，久坐行为和缺乏身体活动是可改变的因素。移动医疗（mHealth）应用程序为T2D管理提供了补充策略，但它们对临床结果的影响尚不清楚。目的：本研究评估了临床实践中提倡“少坐多动”的移动健康计划对患有T2D的办公室员工的临床和心血管风险因素的影响。方法：一项随机对照试验将常规护理（n = 25）与使用Walk@Work-App和基于网络的工具进行为期13周的mHealth干预（n = 29）进行比较。结果包括HbA1c、血糖、血脂、特定领域的久坐行为（Workforce Sitting Questionnaire）、客观体力活动和久坐行为（ActivPal）、基线、6个月和12个月时的血压和BMI。结果：与对照组和12个月时相比，干预组的HbA1c显著降低（p ）。结论：移动健康计划有效地减少了久坐行为，改善了HbA1c和血压，是一种具有成本效益的t2dm成人生活方式干预。试验注册：ClinicalTrials.gov NCT04092738.https://clinicaltrials.gov/ct2/show/NCT04092738。

{"title":"Impact of a primary care-based mobile health intervention to ‘sit less and move more’ on HbA1c, blood pressure, and other clinical outcomes in office employees with type 2 diabetes: A randomized controlled trial","authors":"Francesc Alòs , Ma Àngels Colomer , Judit Bort-Roig , Carlos Martin-Cantera , Alicia Minaya , Ignasi Saigí , Miquel Sitjar-Suñer , Anna Puig-Ribera","doi":"10.1016/j.pcd.2025.05.010","DOIUrl":"10.1016/j.pcd.2025.05.010","url":null,"abstract":"<div><h3>Background</h3><div>Type 2 diabetes (T2D) is a prevalent and costly disease, with sedentary behaviour and physical inactivity as modifiable contributors. Mobile health (mHealth) applications provide complementary strategies for T2D management, but their impact on clinical outcomes remains unclear.</div></div><div><h3>Objective</h3><div>This study evaluated the efficacy of an mHealth programme promoting “sit less and move more” at work, prescribed in clinical practice, on clinical and cardiovascular risk factors in office employees with T2D.</div></div><div><h3>Methods</h3><div>A randomized controlled trial compared usual care (n = 25) with a 13-week mHealth intervention (n = 29) using the Walk@Work-App and web-based tools. Outcomes included HbA1c, glycemia, lipid profile, domain-specific sedentary behaviour (Workforce Sitting Questionnaire), objective physical activity and sedentary behaviour (ActivPal), blood pressure, and BMI at baseline, 6, and 12 months.</div></div><div><h3>Results</h3><div>Compared to the control group and at 12 months, the intervention group showed a significant reduction in HbA1c (p < 0.05), systolic and diastolic blood pressure (p < 0.05). Sitting time decreased during leisure activities while watching TV (p = 0.0052) and using electronic devices (p = 0.0397). The number of sedentary breaks and time spent in sedentary bouts <20 min/day increased (p < 0.05).</div></div><div><h3>Conclusions</h3><div>An mHealth programme effectively reduced sedentary behaviour, improved HbA1c and blood pressure, serving as a cost-effective lifestyle intervention for adults with T2D.</div></div><div><h3>Trial registration</h3><div>ClinicalTrials.gov NCT04092738.<span><span>https://clinicaltrials.gov/ct2/show/NCT04092738</span><svg><path></path></svg></span></div></div>","PeriodicalId":48997,"journal":{"name":"Primary Care Diabetes","volume":"19 5","pages":"Pages 434-445"},"PeriodicalIF":2.3,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144268296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Primary Care Diabetes

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀